Floatz logo

Cediranib

Advanced Digestive System Neuroendocrine Neoplasm

M.D. Anderson Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Advanced Digestive System Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
Ribociclib
M.D. Anderson Cancer Center
Phase 2B
Letrozole
M.D. Anderson Cancer Center
Phase 2B
FULVESTRANT
M.D. Anderson Cancer Center
Phase 2B
Zoladex
M.D. Anderson Cancer Center
Phase 2B
LEUPROLIDE
M.D. Anderson Cancer Center
Phase 2B
Abemaciclib
University of Washington
Phase 2CCC

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →